Diagnostik und Therapie der chronischen pulmonalen Hypertonie

Diese Leitlinie ist eine wissenschaftlich und sys− tematisch erarbeitete Stellungnahme der Deut− schen Gesellschaft für Kardiologie−, Herz− und Kreislaufforschung (DGK), der Deutschen Gesell− schaft für Pneumologie und Beatmungsmedizin (DGP) und der Deutschen Gesellschaft für pädiat− rische Kardiologie (DGPK), die den gegenwärti− gen Erkenntnisstand zum Thema wiedergibt und allen behandelnden Ärzten und ihren Patienten die Entscheidungsfindung für eine angemessene Behandlung dieser spezifischen Krankheitssitua− tion erleichtern soll. Diese Leitlinie ersetzt nicht die ärztliche Evaluation des individuellen Patien− ten und die Anpassung der Diagnostik und Thera− pie an die spezifische Situation des einzelnen Pa− tienten. Die Entwicklung Evidenz−basierter Leitlinien ist durch eine systematische Aufarbeitung und Zu− sammenstellung der besten verfügbaren wissen− schaftlichen Evidenz gekennzeichnet. Die Herlei− tung des in der Leitlinie vorgeschlagenen Vorge− hens ergibt sich allein aus der wissenschaftlichen Evidenz von Studien, wobei randomisierte, kon− trollierte Studien bevorzugt werden. Der Zusam− menhang zwischen der jeweiligen Empfehlung und der zugehörigen Evidenz−Stufe ist gekenn− zeichnet. Empfehlungsgrad Definition I Evidenz und/oder allgemeine Übereinkunft, dass eine Therapieform oder eine diagnosti− sche Maßnahme effektiv, nützlich oder heil− sam ist II Widersprüchliche Evidenz und/oder unter− schiedliche Meinungen über den Nutzen/die Effektivität einer Therapieform oder einer diagnostischen Maßnahme II a Evidenzen/Meinungen favorisieren den Nut− zen bzw. die Effektivität einer Maßnahme II b Nutzen/Effektivität einer Maßnahme ist weniger gut durch Evidenzen/Meinungen belegt Evidenzniveau Definition A Die Empfehlung wird mindestens durch zwei randomisierte Studien gestützt B Die Empfehlung wird durch eine randomi− sierte Studie und/oder eine Metaanalyse nicht−randomisierter Studien gestützt C Konsensus−Meinung von Experten basierend auf Studien und klinischer Erfahrung Im Text werden Empfehlung und Evidenzniveau, wenn verfügbar, in Klammern angegeben. So wird z.B. der Empfehlungsgrad I mit der Evidenz B dargestellt als (I, B).

[1]  E. Hachulla Effects of Beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension : a randomized, double-blind, placebo-controlled trial. , 2008 .

[2]  F. Herth,et al.  Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension , 2006, Circulation.

[3]  R. Barst,et al.  Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. , 2006, Journal of the American College of Cardiology.

[4]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[5]  T. Welte,et al.  Goal-oriented treatment and combination therapy for pulmonary arterial hypertension , 2005, European Respiratory Journal.

[6]  M. Gatzoulis,et al.  BREATHE-5: BOSENTAN IMPROVES HEMODYNAMICS AND EXERCISE CAPACITY IN THE FIRST RANDOMIZED PLACEBO-CONTROLLED TRIAL IN EISENMENGER PHYSIOLOGY , 2005 .

[7]  D. Badesch,et al.  Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.

[8]  Andres Esteban,et al.  Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. , 2005, Chest.

[9]  M. Humbert,et al.  Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension , 2005, Circulation.

[10]  Horst Olschewski,et al.  Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. , 2004, European heart journal.

[11]  T. Welte,et al.  Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension , 2004, European Respiratory Journal.

[12]  C. Bartram,et al.  Primary Pulmonary Hypertension in Children May Have a Different Genetic Background Than in Adults , 2004, Pediatric Research.

[13]  W. Seeger,et al.  Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[14]  A. Torbicki,et al.  Diagnosis and differential assessment of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[15]  P. Corris,et al.  Interventional and surgical modalities of treatment for pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[16]  R. Speich,et al.  Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[17]  Paolo Prandoni,et al.  Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. , 2004, The New England journal of medicine.

[18]  B. Sastry,et al.  Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.

[19]  J. Benson,et al.  Hepatopulmonary syndrome and portopulmonary hypertension: A report of the multicenter liver transplant database , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[20]  F. Reichenberger,et al.  Atrial septostomy in the treatment of severe pulmonary arterial hypertension , 2003, Thorax.

[21]  W. Seeger,et al.  Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[22]  K. Wasserman,et al.  Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[23]  W. Seeger,et al.  Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. , 2003, American journal of respiratory and critical care medicine.

[24]  W. Seeger,et al.  Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial , 2002, The Lancet.

[25]  Gilles Garcia,et al.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.

[26]  W. Seeger,et al.  Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[27]  R. Hetzer,et al.  Assessment of Survival in Patients With Primary Pulmonary Hypertension: Importance of Cardiopulmonary Exercise Testing , 2002, Circulation.

[28]  R. Ewert,et al.  Peripheral airway obstruction in primary pulmonary hypertension , 2002, Thorax.

[29]  M. Humbert,et al.  Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.

[30]  G. Koch,et al.  Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. , 2002, Journal of the American College of Cardiology.

[31]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[32]  M. Rubenfire,et al.  Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[33]  H. Worth,et al.  [Guidelines to long-term oxygen therapy]. , 2001, Pneumologie.

[34]  C. Fischer,et al.  Abnormal Pulmonary Artery Pressure Response in Asymptomatic Carriers of Primary Pulmonary Hypertension Gene , 2000, Circulation.

[35]  S. Hodge,et al.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.

[36]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[37]  W. Seeger,et al.  Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial , 2000, Annals of Internal Medicine.

[38]  M. Fujita,et al.  Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.

[39]  W. Seeger,et al.  Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. , 1999, American journal of respiratory and critical care medicine.

[40]  R. Barst,et al.  Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. , 1999, Circulation.

[41]  G. Maislin,et al.  Vasodilator therapy for primary pulmonary hypertension in children. , 1999, Circulation.

[42]  J B Seward,et al.  Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. , 1998, The American journal of cardiology.

[43]  F. Harrell,et al.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). , 1997, American heart journal.

[44]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[45]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[46]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[47]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.

[48]  A. Ducoloné,et al.  Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. , 1981, Thorax.

[49]  K. C. Lewis Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan , 2007 .

[50]  Avid,et al.  BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .

[51]  P. Walser,et al.  Normal Values for Pulmonary Hemodynamics at Rest and during Exercise in Man , 1975 .